EN PL
CASE REPORT
Lower leg soft tissue abscess caused by Salmonella sp. in a patient with rheumatoid arthritis treated with adalimumab
 
More details
Hide details
 
Online publication date: 2011-05-06
 
 
Reumatologia 2011;49(2):142-145
 
KEYWORDS
ABSTRACT
The use of biological drugs, which include among others anti-tumour necrosis factor α antibody therapy (ATNFαT), may be related to increased incidence of bacterial, viral and fungal infections. Inhibition of the immune system changes the clinical course of infection compared to immunocompetent individuals. Usually an infection has a tendency to generalize or to a symptomless course of the disease. A case of a 60-year-old woman suffering from aggressive rheumatoid arthritis (for 12 years), diabetes mellitus, treated with adalimumab, methotrexate and prednisone with a diagnosis of abscess of the right lower leg soft tissue with aetiology caused by Salmonella sp. is presented (Fig. 1, 2). Appearance of infiltration was preceded by fever. The therapy applied included antibiotics in compliance with antibiogram and surgical treatment (drugs acting as topical disinfectants, accompanied by a regular change of drains), giving a very good clinical effect (Fig. 3) as a result of immunosupresive drugs use. The emergence of the abscess was probably preceded by symptomless Salmonella infection and bacteraemia. One should also take into account the possibility of a carrier-state and reactivation of latent infection. During diagnosis and treatment methotrexate and adalimumab were withdrown. Because of the ever increasing number of patients using biological agents, it is worth noting how unusual course and aetiology an infection may have in these patients. A decision on re-introduction of disease modifying anti-rheumatic drugs or re-qualification of the patient for biological treatment would be taken after the antibiotic therapy is completed.
 
REFERENCES (8)
1.
Wiland P. Leczenie biologiczne chorób reumatycznych. Wydanie I. Termedia, Poznań 2009; 157-175.  .
 
2.
Herold G. Medycyna wewnętrzna. Wydanie III. Wydawnictwo Lekarskie PZWL, Warszawa 2002; 951-955.  .
 
3.
Korzeniewska-Koseła M. Zapobieganie gruźlicy u chorych le­czonych antagonistami czynnika martwicy nowotworów. Reumatologia 2010; 48: 4-13.  .
 
4.
Pablos J, Aragon A, Gomez-Reino J. Salmonellosis and systemic lupus erythematosus. Report of ten cases. Br J Rheumatol 1994; 33: 129-132.  .
 
5.
Adamek A. Bakteryjne zatrucia pokarmowe. Puls Medycyny 2007; 10: 153.  .
 
6.
Román-Ivorra J, Salvador-Suarez F, Abad-Franch L, et al. Incidence of moderate/severe infections in patients treated with anti-TNF. Ann Rheum Dis 2005; 64: 468.  .
 
7.
Pen~a-Sagredo J, Farin~as M, Pérez-Zafrilla B, et al. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-αlpha antagonist therapy. Clin Exp Rheumatol 2009; 27: 920-925.  .
 
8.
Van Diepen A, Martina C, Flierman R, et al. Treatment with anti-TNF alpha does not induce reactivation of latent Salmonella enteric serovar Typhimurium infection in C3H/HeN mice. Scand J Immunol 2007; 65: 407-411.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top